Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic
The Federal Circuit on Tuesday refused AstraZeneca AB's request for an en banc rehearing of its patent dispute over Hanmi Pharmaceutical Co. Ltd.'s generic version of AstraZeneca's acid reflux drug Nexium,...To view the full article, register now.
Already a subscriber? Click here to view full article